Answers are grounded in this paper and cite their sources.
Background So far, CAR T-cell therapy has not been successful in solid tumors, due to several factors including heterogeneous expression of target antigens and a hostile tumor microenvironment. The immune checkpoint molecule B7-H3 is highly expressed on solid cancers and cancer-associated fibroblasts, but hardly detectable on healthy tissue, and thus a promising target for immunotherapy.
No takes yet. Share an insight, caveat, or question.
Scheckenbach et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: